Better Buy: GlaxoSmithKline vs. Merck
Healthcare is big business, and investors looking for stable, long-term growth stocks should look no further than Merck & Co. (NYSE: MRK) and GlaxoSmithKline (NYSE: GSK). Both are significant players in the pharmaceutical industry, and both companies offer investors some great investment options with low volatility that pay dividends.
Let's take a closer look to see which of these is the better option today.
Despite showing some impressive growth in its most recent quarter, Merck's share price has risen just 10% in 2019. It has been carried in part by the strong success of Keytruda, a cancer-fighting drug that could be integral to the company's long-term success. With Keytruda improving the survival rate of patients suffering from lung cancer, there's a lot of potential to help Merck generate even more success in the years to come, especially as it receives approval to use Keytruda for more treatment options. Most recently, the U.S. Food and Drug Administration gave it the OK for treating certain types of melanoma.
Source Fool.com
